Full Press Release Details
Vittal R, Fisher A, Gu H, et al. Peptide-Mediated Inhibition of Mitogen-Activated Protein Kinase Activated Protein Kinase 2 Ameliorates Bleomycin-Induced Pulmonary Fibrosis. Am J Respir Cell Mol Biol. 2013;49(1):47 57. doi: 10.1165/rcmb.2012-0389OC 23. Liang J, Liu N, Liu X, et al. Mitogen-activated Protein Kinase activated Protein Kinase 2 Inhibition Attenuates Fibroblast Invasion and Severe Lung Fibrosis.
Plasma IL-1 Beta and IL-6 Levels Are Consistent and Efficient Predictors of Outcome Over Time. Chest. 1995;107(4):1062-1073. doi: 10.1378/chest.107.4.1062 21. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21. doi: 10.1016/S2213- 2600(20)30116-8 22.
N Engl J Med. 2011;364(14):1293-1304. doi: 10.1056/NEJMoa1011802 19. Borthwick LA. The IL-1 Cytokine Family and Its Role in Inflammation and Fibrosis in the Lung. Semin Immunopathol. 2016;38(4):517-34. doi: 10.1007/s00281-016-0559-z 20. Meduri GU, Headley S, Kohler G, Stentz F, Tolley E, Umberger R, Leeper K. Persistent Elevation of Inflammatory Cytokines Predicts a Poor Outcome in ARDS.
PLoS Pathog. 2014;10(8):1-20. doi: 10.1371/journal.ppat.1004320 17. Spagnolo P, Balestro E, Aliberti S, et al. Pulmonary fibrosis secondary to COVID-19: a call to arms? Lancet Respir Med. Published online May 15, 2020. doi: 10.1016/ S2213- 2600(20)30222-8 18. Herridge MS, Tansey CM, Matt A, et al. Functional Disability 5 Years after Acute Respiratory Distress Syndrome.
MAP kinase-activated protein kinases 2 and 3 are required for influenza A virus propagation and act via inhibition of PKR. FASEB J. 2010; 24:4068- 4077. doi: 10.1096/fj.10-158766 16. Jimenez-Guarde o JM, Nieto-Torres JL, DeDiego ML, et al. The PDZ-Binding Motif of Severe Acute Respiratory Syndrome Coronavirus Envelope Protein Is a Determinant of Viral Pathogenesis.
Mol Therapy: Nuc Acids. 2017;7:256- 266. doi: 10.1016/j.omtn.2017.03.008 14. Yoshino S, Mizutani N. Intranasal exposure to monoclonal antibody Fab fragments to Japanese cedar pollen Cry j1 suppresses Japanese cedar pollen induced allergic rhinitis. Br J Pharmacol. 2016;173(10):1629 1638. doi: 10.1111/bph.13463 15. Luig C, K ther K, Dudek SE, et al.
J Virol. 2011;420(2):106-116. doi: 10.1016/j.virol.2011.09.003 12. Cascella M, Rajnik M, Cuomo A, Dulebohn S. Features, Evaluation and Treatment Coronavirus (COVID-19). StatPearls. Updated May 18, 2020. Accessed June 16, 2020. https://www.statpearls.com/kb/viewarticle/52171 13. McCaskill JL, Ressel S, Alber A, et al. Broad-Spectrum Inhibition of Respiratory Virus Infection by MicroRNA Mimics Targeting p38 MAPK Signaling.
Activation of p38 MAPK by feline infectious peritonitis virus regulates pro-inflammatory cytokine production in primary blood-derived feline mononuclear cells. J Virol. 2009;384(1):135-143. doi: 10.1016/j.virol.2008.11.006 11. Liao Y, Wang X, Huang M, Tam JP, Liu DX. Regulation of the p38 mitogen-activated protein kinase and dual-specificity phosphatase 1 feedback loop modulates the induction of interleukin 6 and 8 in cells infected with coronavirus infectious bronchitis virus.
Viruses. 2016;8(7):184. doi: 10.3390/v8070184 9. Banerjee S, Narayanan K, Mizutani T, Makino S. Murine Coronavirus Replication-Induced p38 Mitogen-Activated Protein Kinase Activation Promotes Interleukin-6 Production and Virus Replication in Cultured Cells. J Virol. 2002;76(12):5937-5948. doi:10.1128/JVI.76.12.5937 5948.2002 10. Regan, AD, Cohen RD, Whittaker GR.
ClinicalTrials.gov Identifier: NCT04403685. Accessed June 16, 2020. https://www.clinicaltrials.gov/ct2/show/NCT04403685 7. Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19. ClinicalTrials.gov Identifier: NCT04347226. Accessed June 15, 2020. https://www.clinicaltrials.gov/ct2/show/NCT04347226 8. Fung TS, Liao Y, Liu DX. Regulation of Stress Responses and Translational Control by Coronavirus.
Accessed June 15, 2020. https://www.clinicaltrials.gov/ct2/show/NCT04376684 5. Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia (CAN-COVID). ClinicalTrials.gov Identifier: NCT04362813. Accessed June 15, 2020. https://www.clinicaltrials.gov/ct2/show/NCT04362813 6. Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers (TOCIBRAS).
Lancet. 2020;395:1054-1062. doi: 10.1016/S0140-6736(20)30566-3 3. Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020;117(20):10970-10975. doi: 10.1073/pnas.2005615117 4. Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease (OSCAR). ClinicalTrials.gov Identifier: NCT04376684.
This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. Cautionary Note Regarding Forward-Looking Statements 2 Copyright 2020 Aclaris Therapeutics, Inc.
Securities and Exchange Commission from time to time. These documents are available under the SEC filings" section of the Investors page of Aclaris' website at http://www.aclaristx.com. Any forward-looking statements speak only as of the date of this presentation and are based on information available to Aclaris as of the date of this presentation, and Aclaris assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry.
These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Aclaris' reliance on third parties over which it may not always have full control, the uncertainty regarding the COVID-19 pandemic including its impact on the timing of Aclaris' regulatory and research and development activities, and other risks and uncertainties that are described in the Risk Factors section of Aclaris' Annual Report on Form 10-K for the year ended December 31, 2019, Aclaris' Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 and other filings Aclaris makes with the U.S.
These statements may be identified by words such as "believe, "expect," "may, "plan," "potential," "will," and similar expressions, and are based on Aclaris' current beliefs and expectations. These forward-looking statements include expectations regarding ATI-450 as a potential treatment for patients with COVID-19 and the clinical development of ATI-450.
Am J Respir Cell Mol Biol. 2019;60(1):41 48. doi: 10.1165/rcmb.2018-0033OC